SCHEMBL23796014

SCHEMBL23796014

COC(=O)c1cnc2c(-c3ccc(C(F)(F)F)cc3)cc(OC)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.46
KDR P35968 2/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
LMNA P02545 1/20 0.44
PSMD14 O00487 1/20 0.43
MYC P01106 1/20 0.43
MAX P61244 1/20 0.43
MAOB P27338 2/20 0.42
PTPN1 P18031 1/20 0.42
PTPN11 Q06124 2/20 0.42
MAPT P10636 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23795934 0.90 PTPN11 (0.49) MAOBPTPN11PTGDR2
SCHEMBL30301859 0.90 CYP11B1 (0.46) PDGFRBKDRCYP11B1CYP11B2PSMD14
SCHEMBL25071152 0.90 CYP11B1 (0.46) PDGFRBKDRCYP11B1CYP11B2PSMD14
SCHEMBL25071241 0.90 CYP11B1 (0.46) PDGFRBKDRCYP11B1CYP11B2LMNA
SCHEMBL30301842 0.89 CYP11B1 (0.47) CYP11B1CYP11B2PSMD14
SCHEMBL25070964 0.89 CYP11B1 (0.47) CYP11B1CYP11B2PSMD14
SCHEMBL23796480 0.87 HPGDS (0.51) PSMD14MAOBPTPN11MAPTPTGDR2
SCHEMBL23796316 0.86 PDGFRB (0.44) PDGFRBKDRCYP11B1CYP11B2LMNA
SCHEMBL23796013 0.84 PSMD14 (0.56) PDGFRBKDRLMNAPSMD14MYC
SCHEMBL28624905 0.84 HDAC4 (0.46) PSMD14PTGDR2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866431-B2 Bicyclic compounds VIVACE THERAPEUTICS, INC. (US) 2024-01-09 US disclosed
US-20230061429-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2023-03-02 US disclosed
EP-3877356-A1 BICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-09-15 EP disclosed
CN-113302175-A Bicyclic compounds 维瓦斯治疗公司 2021-08-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11866431-B2 Bicyclic compounds YAP1, MYC, TEAD2 PDGFRB 2236/4885KDR 2107/4885CYP11B1 734/4885
US-20230061429-A1 BICYCLIC COMPOUNDS YAP1, MYC, TEAD2 PDGFRB 2236/4885KDR 2107/4885CYP11B1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.